In a one-year study researchers discovered great benefits and found that the drug "Dostarlimab", which is used to treat endometrial cancer in women, helped heal 18 people with colorectal cancer, who participated in this clinical trial.

Commenting on this medical discovery, a member of the American National Cancer Advisory Board, and lead author of the study, Dr. Louis Diaz, said the experiment was "an important step in the battle against cancer. We will do more research to find out the effect of the drug on other types of cancer such as stomach, prostate and pancreas, "according to the British Daily Mail.

According to the researchers, "dostarlimab" can be used with patients with tumors with a specific genetic composition known as micro-satellite instability or MSI.

The drug's monoclonal antibody works by binding to a protein called PD-1 on the surface of cancer cells, helping the immune system effectively destroy cancer cells.

The researchers confirmed in the study published in the New England Journal of Medicine that: "At the time of reporting, no patients received chemotherapy, radiation or surgery, and no cases of development or recurrence of cancer during follow-up were reported."

Despite the promising results of the "miracle" drug, the researchers emphasized the need for more research on more people, monitoring the length of time to take the drug, and evaluating the few side effects of the experiment.

Some 43 thousand Britons and 150,000 Americans are diagnosed with colorectal cancer each year and kill 17 53,000 annually in both the UK and America.